XORTX Therapeutics Inc. Common Stock (XRTX) Stock Price

XRTXStock

$2.34−67.95%52W

Market Cap$4.25M

P/E—

PEG Ratio—

Div yield—

Beta0.03

XRTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.09%

Price vs S&P 500 (4W)0.17%

VGM Score60.39

Book Value / Share (Quarterly)$0.92

P/TBV (Annual)2.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-20.19%

Cash Flow / Share (Quarterly)$-1.93

Price vs S&P 500 (YTD)-31.88%

Gross Margin (TTM)21.01%

Net Profit Margin (TTM)-2.60%

EPS (TTM)$-2.65

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-2.65

EPS (Annual)$-2.81

ROI (Annual)-125.19%

Gross Margin (Annual)21.01%

Cash / Share (Quarterly)$0.18

ROA (Last FY)-98.99%

EBITD / Share (TTM)$-2.71

ROE (5Y Avg)-78.68%

Operating Margin (TTM)-0.27%

Cash Flow / Share (Annual)$-2.03

P/B Ratio2.88x

P/B Ratio (Quarterly)2.18x

Net Income / Employee (Annual)$-885,400

Net Interest Coverage (TTM)-131.30x

ROA (TTM)-106.58%

EPS Incl Extra (Annual)$-2.81

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)0.80x

3-Month Avg Trading Volume0.00M

52-Week Price Return-67.95%

Revenue / Employee (TTM)$271,440,000

Tangible BV / Share (Quarterly)$0.79

P/S Ratio (Annual)0.00x

Asset Turnover (Annual)2.01x

52-Week High$9.85

EPS Excl Extra (Annual)$-2.81

CapEx CAGR (5Y)38.81%

26-Week Price Return10.91%

Quick Ratio (Annual)2.07x

13-Week Price Return-13.84%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.86x

Enterprise Value$3.47M

Asset Turnover (TTM)1.88x

Revenue / Employee (Annual)$271,440,000

Inventory Turnover (Annual)4.23x

Pretax Margin (Annual)-0.24%

Cash / Share (Annual)$0.62

3-Month Return Std Dev76.04%

Net Income / Employee (TTM)$-922,000

ROE (Last FY)-127.43%

Net Interest Coverage (Annual)-0.77x

EPS Basic Excl Extra (Annual)$-2.81

P/FCF (TTM)7.03x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-2.65

Receivables Turnover (Annual)15.35x

ROI (TTM)-146.27%

P/S Ratio (TTM)0.00x

Revenue / Share (Annual)$29.65

Tangible BV / Share (Annual)$1.36

Price vs S&P 500 (52W)-67.56%

Year-to-Date Return-20.78%

5-Day Price Return9.71%

EPS Normalized (Annual)$-2.81

ROA (5Y Avg)-57.85%

Net Profit Margin (Annual)-2.60%

Month-to-Date Return7.39%

Cash Flow / Share (TTM)$-4.98

EBITD / Share (Annual)$-3.32

Operating Margin (Annual)-0.27%

LT Debt / Equity (Annual)0.13x

ROI (5Y Avg)-77.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.65

P/TBV (Quarterly)2.55x

P/B Ratio (Annual)1.90x

Pretax Margin (TTM)-0.24%

Book Value / Share (Annual)$1.50

Price vs S&P 500 (13W)-16.59%

Beta0.03x

P/FCF (Annual)47.05x

Revenue / Share (TTM)$29.55

ROE (TTM)-150.08%

52-Week Low$2.42

vGradeB

mGradeC

vgmGradeB

XRTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Feb 27, 2026	-$1.58	-$0.45	+71.47%(+$1.13)
Q3 2025	Nov 15, 2025	-$1.58	-$1.02	+35.22%(+$0.56)

XRTX Analyst Recommendations

Dec 2023

Jan 2024

Feb 2024

Mar 2024

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
XRTXXORTX Therapeutics Inc. Common Stock	B	—	C	$2.34
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About XORTX Therapeutics Inc. Common Stock

XORTX Therapeutics is a clinical-stage biotechnology company developing therapies for progressive kidney disease by targeting purine and uric acid metabolism. The company is advancing three therapeutic candidates for rare kidney disease indications including ADPKD and Type 2 Diabetic Nephropathy, as well as acute kidney injury associated with respiratory infections. The company aims to slow or reverse chronic kidney disease progression and explore additional indications leveraging its intellectual property.